Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 16,000 shares at $75.46 ($1.2M) on 2024-05-20, disclosed to the SEC on 2024-05-22.
Scheduled sale ($1.2M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.40 | 3,544 | $264K | 22.0% |
| 2 | $74.40 | 3,544 | $264K | 22.0% |
| 3 | $75.46 | 4,456 | $336K | 28.0% |
| 4 | $75.46 | 4,456 | $336K | 28.0% |
| Total | $74.99 avg | 16,000 | $1.2M | 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |